Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02947373 · ClinicalTrials.gov registry record · Phase 1

Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors

A Phase 1 study of Pediatric Brain Tumors, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT02947373 is a Phase 1 study of Pediatric Brain Tumors that has completed, run by University of California, San Francisco. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02947373, a Phase 1 study of Pediatric Brain Tumors, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This is a single arm pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The pilot study will look at the safety and toxicity of acquiring hyperpolarized carbon-13 imaging in children with brain tumors.

Conditions Studied

Interventions

  • DRUG Hyperpolarized Pyruvate

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2017-01-25
Est. Completion 2020-07-31
Phase Phase 1

What the Registry Record Tells You About NCT02947373

The ClinicalTrials.gov registry entry for NCT02947373 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pediatric Brain Tumors appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized Pyruvate is the first listed.

NCT02947373 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02947373 about?

NCT02947373 is a clinical study titled "Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors". This is a single arm pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The pilot study will look at the safety and toxicity of acquiring hyperpolarized carbon-13 imaging in children with brain tumors.

What is the current status of trial NCT02947373?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-01-25. Estimated completion is 2020-07-31.

What conditions does trial NCT02947373 study?

This clinical trial studies the following conditions: Pediatric Brain Tumors.

What interventions are being tested in trial NCT02947373?

The interventions under investigation include: Hyperpolarized Pyruvate (DRUG).

Who is sponsoring clinical trial NCT02947373?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02947373 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pediatric Brain Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.